Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
SNY similar filings
- 25 Apr 24 Sales growth of 6.7% at CER and business EPS(1) of €1.78
- 20 Mar 24 New Phase 2b results for amlitelimab support potential for best-in-class maintenance of response in atopic dermatitis
- 27 Feb 24 Current report (foreign)
- 15 Feb 24 Current report (foreign)
- 2 Feb 24 Approval based on Phase 3 EoE KIDS trial showing a greater proportion of children taking Dupixent achieved histological remission compared to placebo
- 1 Feb 24 Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
- 23 Jan 24 Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline
Filing view
External links